GlassScriptPhysician profile
Bassel Hassouna
NPI 1780918946
$24,809.69
in general payments reported to CMS, 2019-2025
41 companies · $7,286 in 2025
The $7,286 reported for 2025 was more than what 87% of Interventional Cardiology providers received nationally (typical 2025 total: $1,092).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $66.57 · 2021: $1,182 · 2022: $1,257 · 2023: $5,604 · 2024: $9,413 · 2025: $7,286.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Long Term Medical Supply Or Device Loan: $18K · Food and Beverage: $4,512.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Long Term Medical Supply Or Device Loan | $17,791.66 |
| Food and Beverage | $4,512.08 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Angiodynamics, INC. | $17,826.52 | 2022-2025 | Auryon Laser System 100-120 Vac |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $910.76 | 2022-2025 | Lifevest |
| Merck Sharp & Dohme LLC | $559.01 | 2021-2025 | Verquvo, Capvaxive |
| Janssen Pharmaceuticals, INC | $543.21 | 2021-2024 | Xarelto |
| Boehringer Ingelheim Pharmaceuticals, INC. | $492.83 | 2021-2024 | Jardiance |
| Astrazeneca Pharmaceuticals LP | $460.33 | 2021-2025 | Farxiga, Wainua |
| E.R. Squibb & Sons, L.L.C. | $357.73 | 2021-2025 | Eliquis, Camzyos |
| Kestra Medical Technology Services, INC. | $322.59 | 2023-2025 | Assure Wcd |
| Novartis Pharmaceuticals Corporation | $279.11 | 2021-2025 | |
| Tactile Systems Technology INC | $247.38 | 2024-2025 | Flexitouch Plus, Entre Plus, Nimbl |
| Astellas Pharma US INC | $198.99 | 2022 | |
| Shockwave Medical, INC | $180.97 | 2021 | |
| Inari Medical, INC. | $180.37 | 2021 | |
| Actelion Pharmaceuticals US, INC. | $157.64 | 2024-2025 | Uptravi, Opsumit |
| Novo Nordisk INC | $156.90 | 2021-2024 | Ozempic, Rybelsus |
Show all 41 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Imperative Care, INC | $149.66 | 2025 | Symphony Catheter |
| Bayer Healthcare Pharmaceuticals INC. | $143.87 | 2021-2022 | |
| Penumbra, INC. | $141.88 | 2024 | Indigo System |
| Glaxosmithkline, LLC. | $138.05 | 2021-2023 | Trelegy Ellipta, Shingrix |
| Lexicon Pharmaceuticals, INC. | $136.99 | 2023-2024 | Inpefa |
| Cardiovascular Systems INC. | $133.83 | 2023 | Diamondback Peripheral |
| Lilly USA, LLC | $122.56 | 2023-2024 | Mounjaro |
| Amgen INC. | $110.68 | 2021-2025 | Repatha |
| Boston Scientific Corporation | $109.80 | 2024 | Watchman Flx |
| Baxter Healthcare | $103.61 | 2023 | Hillrom - Cardiac Ambulatory Monitor |
| Sanofi-Aventis U.S. LLC | $85.89 | 2021-2023 | |
| Philips North America LLC | $77.78 | 2022-2023 | |
| Kiniksa Pharmaceuticals International, Plc | $76.48 | 2024 | Arcalyst |
| Cook Medical LLC | $66.57 | 2019 | |
| Cordis US Corp. | $65.13 | 2024-2025 | Mynx Control, Mynxgrip |
| Pfizer INC. | $58.04 | 2023-2025 | |
| Impulse Dynamics (USA) INC. | $37.75 | 2024 | Optimizer |
| Cvrx, INC. | $30.38 | 2023 | Barostim Neo System |
| Alnylam Pharmaceuticals INC. | $24.10 | 2022 | |
| Abbott Laboratories | $23.03 | 2022 | |
| Regeneron Healthcare Solutions, INC. | $20.85 | 2022 | |
| Heartflow, INC. | $18.94 | 2023 | Ffrct |
| American Regent | $17.98 | 2024 | Injectafer |
| Edwards Lifesciences Corporation | $16.44 | 2022 | |
| Teleflex LLC | $12.92 | 2022 | |
| Bardy Diagnostics, INC. | $12.14 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Bassel Hassouna listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.